CBP-501 acetate is a cell-permeable calmodulin-binding peptide and a G2-abrogating drug candidate. It inhibits the activity of multiple Ser216-specific kinases, including MAPKAP-K2, C-Tak1, CHK1, and CHK2. It is used for various types of cancer and enhances the cytotoxicity of CDDP and Bleomycin against cancer cells both in vitro and in vivo.
- Inhibits MAPKAP-K2 with an IC50 of 0.9 μM
- Inhibits C-Tak1 with an IC50 of 1.4 μM
- Inhibits Chk1 with an IC50 of 3.4 μM
- Inhibits Chk2 with an IC50 of 6.5 μM
- Stable for 2 years at -80°C as powder
- Stable for 1 year at -20°C as powder
- Stable for 6 months at -80°C in solvent
- Stable for 1 month at -20°C in solvent
- Enhances cytotoxicity of CDDP and Bleomycin